Key result
Eptifibatide during PCI shows no benefit for MACE or survival in NSTEMI.
Why the study?
The long-term effects of Eptifibatide on major adverse cardiac events and survival in NSTEMI patients undergoing PCI remain unclear.
Does eptifibatide reduce major adverse cardiac events (MACE) or improve survival in NSTEMI patients undergoing PCI?
Cohort (n=5,309)
No
Does eptifibatide reduce major adverse cardiac events (MACE) or improve survival in NSTEMI patients undergoing PCI?
The routine use of eptifibatide during PCI for NSTEMI does not significantly improve 1-year MACE or survival compared to standard care.
No outcome benefit seen with eptifibatide in NSTEMI PCI; hypothesis-generating and should not yet change practice.
BACKGROUND: Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during percutaneous coronary intervention (PCI) to prevent clots, but its long-term effects in NSTEMI patients remain unclear. AIMS: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI. METHODS: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences. RESULTS: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901). CONCLUSION: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups.
No takes yet. Share an insight, caveat, or question.
Kalhor et al. (2025) conducted a cohort in Non-ST-elevation myocardial infarction (NSTEMI) (n=5,309). Eptifibatide vs. Standard care (no Eptifibatide) was evaluated on Major adverse cardiac events (MACE) and survival (HR 0.97, p=0.901). Eptifibatide administration during PCI in NSTEMI patients showed no significant effect on MACE (17.2% vs. 15.6%) or survival (HR 0.97, p=0.901).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: